Abatacept for the Treatment of Refractory Juvenile Dermatomyositis
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 06 Nov 2015 New trial record
- 05 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.